Treatment-Resistant Depression

Midwest CEPAC
May 23, 2019 9am- 5pm CT

Hyatt Regency O’Hare
LAX Room
9300 Bryn Mawr Avenue
Rosemont, IL 60018

Evidence Presentation Public Comment Voting Session Policy Roundtable Discussion

The Midwest CEPAC will convene to review evidence on esketamine as a therapy for treatment-resistant depression. The Council will also review a report on siponimod for treatment of secondary progressive MS during this meeting.

Key Dates

Associated Materials

10/10/2018 – 10/30/2018
Open Input Period
10/31/2018
Draft Scoping Document
10/31/2018
Stakeholder List
10/31/2018 – 11/20/2018
Public Comments
11/29/2018
Revised Scoping Document
01/14/2019
Research Protocol
02/04/2019
Model Analysis Plan
03/21/2019
Draft Voting Questions
03/21/2019
Draft Evidence Report
03/21/2019 – 04/17/2019
Public Comments
05/09/2019
Evidence Report
05/09/2019
Revised Voting Questions
05/09/2019
Response to Comments
05/23/2019
Meeting Agenda
05/23/2019
Evidence Presentation
06/20/2019
Final Evidence Report and Meeting Summary
06/20/2019
Report-at-a-Glance